CymaBay Therapeutics - CBAY Stock Forecast, Price & News

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CymaBay Therapeutics Trading Down 0.2 %

CBAY traded down $0.01 during midday trading on Wednesday, reaching $4.07. 13,115 shares of the company's stock traded hands, compared to its average volume of 615,380. CymaBay Therapeutics has a 52 week low of $1.67 and a 52 week high of $4.74. The company has a debt-to-equity ratio of 0.73, a current ratio of 13.68 and a quick ratio of 13.68. The firm has a fifty day moving average of $2.89 and a two-hundred day moving average of $2.84. The stock has a market capitalization of $344.64 million, a price-to-earnings ratio of -3.07 and a beta of 0.68.

CymaBay Therapeutics (NASDAQ:CBAY - Get Rating) last posted its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). During the same quarter in the previous year, the firm earned ($0.25) earnings per share. On average, equities analysts anticipate that CymaBay Therapeutics will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on CBAY shares. HC Wainwright cut their price target on shares of CymaBay Therapeutics from $12.00 to $10.00 and set a "na" rating for the company in a research report on Monday, May 16th. Oppenheimer reduced their price target on CymaBay Therapeutics to $12.00 and set a "na" rating on the stock in a research report on Monday, May 16th. B. Riley lowered their price objective on CymaBay Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, May 18th. Finally, StockNews.com cut shares of CymaBay Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, CymaBay Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $10.80.

Insider Transactions at CymaBay Therapeutics

In related news, CEO Sujal Shah purchased 51,301 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The stock was bought at an average cost of $1.95 per share, with a total value of $100,036.95. Following the completion of the purchase, the chief executive officer now directly owns 171,301 shares in the company, valued at $334,036.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.50% of the company's stock.